Serum 4β-hydroxycholesterol increases during fluconazole treatment
Purpose The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum concentrations of different st...
Saved in:
| Published in: | European journal of clinical pharmacology Vol. 77; no. 5; pp. 659 - 669 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.05.2021
Springer Nature B.V |
| Subjects: | |
| ISSN: | 0031-6970, 1432-1041, 1432-1041 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Purpose
The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum concentrations of different sterols and oxysterols within the cholesterol metabolism to see if this inhibitory reaction is a general side effect of azole antifungal agents.
Methods
In a prospective, double-blind, placebo-controlled, two-way crossover design, we studied 17 healthy subjects (nine men, eight women) who received 400 mg fluconazole or placebo daily for 8 days. On day 1 before treatment and on day 8 after the last dose, fasting blood samples were collected. Serum cholesterol precursors and oxysterols were measured by gas chromatography-mass spectrometry-selected ion monitoring and expressed as the ratio to cholesterol (R_sterol).
Results
Under fluconazole treatment, serum R_lanosterol and R_24,25-dihydrolanosterol increased significantly without affecting serum cholesterol or metabolic downstream markers of hepatic cholesterol synthesis. Serum R_4β-, R_24S-, and R_27-hydroxycholesterol increased significantly.
Conclusion
Fluconazole inhibits the 14α-demethylation of lanosterol and 24,25-dihydrolanosterol, regulated by CYP51A1, without reduction of total cholesterol synthesis. The increased serum level of R_4β-hydroxycholesterol under fluconazole treatment is in contrast to the reductions observed under ketoconazole and itraconazole treatments. The question, whether this increase is caused by induction of CYP3A4 or by inhibition of the catabolism of 4β-hydroxycholesterol, must be answered by mechanistic in vitro and in vivo studies comparing effects of various azole antifungal agents on hepatic CYP3A4 activity. |
|---|---|
| AbstractList | PurposeThe antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum concentrations of different sterols and oxysterols within the cholesterol metabolism to see if this inhibitory reaction is a general side effect of azole antifungal agents.MethodsIn a prospective, double-blind, placebo-controlled, two-way crossover design, we studied 17 healthy subjects (nine men, eight women) who received 400 mg fluconazole or placebo daily for 8 days. On day 1 before treatment and on day 8 after the last dose, fasting blood samples were collected. Serum cholesterol precursors and oxysterols were measured by gas chromatography-mass spectrometry-selected ion monitoring and expressed as the ratio to cholesterol (R_sterol).ResultsUnder fluconazole treatment, serum R_lanosterol and R_24,25-dihydrolanosterol increased significantly without affecting serum cholesterol or metabolic downstream markers of hepatic cholesterol synthesis. Serum R_4β-, R_24S-, and R_27-hydroxycholesterol increased significantly.ConclusionFluconazole inhibits the 14α-demethylation of lanosterol and 24,25-dihydrolanosterol, regulated by CYP51A1, without reduction of total cholesterol synthesis. The increased serum level of R_4β-hydroxycholesterol under fluconazole treatment is in contrast to the reductions observed under ketoconazole and itraconazole treatments. The question, whether this increase is caused by induction of CYP3A4 or by inhibition of the catabolism of 4β-hydroxycholesterol, must be answered by mechanistic in vitro and in vivo studies comparing effects of various azole antifungal agents on hepatic CYP3A4 activity. The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum concentrations of different sterols and oxysterols within the cholesterol metabolism to see if this inhibitory reaction is a general side effect of azole antifungal agents. In a prospective, double-blind, placebo-controlled, two-way crossover design, we studied 17 healthy subjects (nine men, eight women) who received 400 mg fluconazole or placebo daily for 8 days. On day 1 before treatment and on day 8 after the last dose, fasting blood samples were collected. Serum cholesterol precursors and oxysterols were measured by gas chromatography-mass spectrometry-selected ion monitoring and expressed as the ratio to cholesterol (R_sterol). Under fluconazole treatment, serum R_lanosterol and R_24,25-dihydrolanosterol increased significantly without affecting serum cholesterol or metabolic downstream markers of hepatic cholesterol synthesis. Serum R_4β-, R_24S-, and R_27-hydroxycholesterol increased significantly. Fluconazole inhibits the 14α-demethylation of lanosterol and 24,25-dihydrolanosterol, regulated by CYP51A1, without reduction of total cholesterol synthesis. The increased serum level of R_4β-hydroxycholesterol under fluconazole treatment is in contrast to the reductions observed under ketoconazole and itraconazole treatments. The question, whether this increase is caused by induction of CYP3A4 or by inhibition of the catabolism of 4β-hydroxycholesterol, must be answered by mechanistic in vitro and in vivo studies comparing effects of various azole antifungal agents on hepatic CYP3A4 activity. Purpose The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum concentrations of different sterols and oxysterols within the cholesterol metabolism to see if this inhibitory reaction is a general side effect of azole antifungal agents. Methods In a prospective, double-blind, placebo-controlled, two-way crossover design, we studied 17 healthy subjects (nine men, eight women) who received 400 mg fluconazole or placebo daily for 8 days. On day 1 before treatment and on day 8 after the last dose, fasting blood samples were collected. Serum cholesterol precursors and oxysterols were measured by gas chromatography-mass spectrometry-selected ion monitoring and expressed as the ratio to cholesterol (R_sterol). Results Under fluconazole treatment, serum R_lanosterol and R_24,25-dihydrolanosterol increased significantly without affecting serum cholesterol or metabolic downstream markers of hepatic cholesterol synthesis. Serum R_4β-, R_24S-, and R_27-hydroxycholesterol increased significantly. Conclusion Fluconazole inhibits the 14α-demethylation of lanosterol and 24,25-dihydrolanosterol, regulated by CYP51A1, without reduction of total cholesterol synthesis. The increased serum level of R_4β-hydroxycholesterol under fluconazole treatment is in contrast to the reductions observed under ketoconazole and itraconazole treatments. The question, whether this increase is caused by induction of CYP3A4 or by inhibition of the catabolism of 4β-hydroxycholesterol, must be answered by mechanistic in vitro and in vivo studies comparing effects of various azole antifungal agents on hepatic CYP3A4 activity. The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum concentrations of different sterols and oxysterols within the cholesterol metabolism to see if this inhibitory reaction is a general side effect of azole antifungal agents.PURPOSEThe antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity. We tested the effect of another antifungal triazole agent, fluconazole, on serum concentrations of different sterols and oxysterols within the cholesterol metabolism to see if this inhibitory reaction is a general side effect of azole antifungal agents.In a prospective, double-blind, placebo-controlled, two-way crossover design, we studied 17 healthy subjects (nine men, eight women) who received 400 mg fluconazole or placebo daily for 8 days. On day 1 before treatment and on day 8 after the last dose, fasting blood samples were collected. Serum cholesterol precursors and oxysterols were measured by gas chromatography-mass spectrometry-selected ion monitoring and expressed as the ratio to cholesterol (R_sterol).METHODSIn a prospective, double-blind, placebo-controlled, two-way crossover design, we studied 17 healthy subjects (nine men, eight women) who received 400 mg fluconazole or placebo daily for 8 days. On day 1 before treatment and on day 8 after the last dose, fasting blood samples were collected. Serum cholesterol precursors and oxysterols were measured by gas chromatography-mass spectrometry-selected ion monitoring and expressed as the ratio to cholesterol (R_sterol).Under fluconazole treatment, serum R_lanosterol and R_24,25-dihydrolanosterol increased significantly without affecting serum cholesterol or metabolic downstream markers of hepatic cholesterol synthesis. Serum R_4β-, R_24S-, and R_27-hydroxycholesterol increased significantly.RESULTSUnder fluconazole treatment, serum R_lanosterol and R_24,25-dihydrolanosterol increased significantly without affecting serum cholesterol or metabolic downstream markers of hepatic cholesterol synthesis. Serum R_4β-, R_24S-, and R_27-hydroxycholesterol increased significantly.Fluconazole inhibits the 14α-demethylation of lanosterol and 24,25-dihydrolanosterol, regulated by CYP51A1, without reduction of total cholesterol synthesis. The increased serum level of R_4β-hydroxycholesterol under fluconazole treatment is in contrast to the reductions observed under ketoconazole and itraconazole treatments. The question, whether this increase is caused by induction of CYP3A4 or by inhibition of the catabolism of 4β-hydroxycholesterol, must be answered by mechanistic in vitro and in vivo studies comparing effects of various azole antifungal agents on hepatic CYP3A4 activity.CONCLUSIONFluconazole inhibits the 14α-demethylation of lanosterol and 24,25-dihydrolanosterol, regulated by CYP51A1, without reduction of total cholesterol synthesis. The increased serum level of R_4β-hydroxycholesterol under fluconazole treatment is in contrast to the reductions observed under ketoconazole and itraconazole treatments. The question, whether this increase is caused by induction of CYP3A4 or by inhibition of the catabolism of 4β-hydroxycholesterol, must be answered by mechanistic in vitro and in vivo studies comparing effects of various azole antifungal agents on hepatic CYP3A4 activity. |
| Author | Kerksiek, Anja Lötsch, Jörn Lütjohann, Dieter Stellaard, Frans Oertel, Bruno G |
| Author_xml | – sequence: 1 givenname: Dieter orcidid: 0000-0002-7941-8308 surname: Lütjohann fullname: Lütjohann, Dieter email: dieter.luetjohann@ukbonn.de organization: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn – sequence: 2 givenname: Frans orcidid: 0000-0002-0362-7330 surname: Stellaard fullname: Stellaard, Frans organization: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn – sequence: 3 givenname: Anja surname: Kerksiek fullname: Kerksiek, Anja organization: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn – sequence: 4 givenname: Jörn surname: Lötsch fullname: Lötsch, Jörn organization: Institute of Clinical Pharmacology, Goethe-University Frankfurt, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP – sequence: 5 givenname: Bruno G surname: Oertel fullname: Oertel, Bruno G organization: Institute of Clinical Pharmacology, Goethe-University Frankfurt, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33201347$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1uFDEQhS2UiEwCF2CBWmLDxqTKdv9tkNCIPylSFmRvud3VGUfd9mB3I4ZjcRDOhIcJgWSRlWXV96pe1TtlRz54YuwFwhsEqM8TgBANBwEcJCjk5RO2QiUFx_w7YisAibxqazhhpyndAGDZgnzKTqQUgFLVK7b-QnGZCvXrJ9_s-hi-7-wmjJRmimEsnLeRTKJU9Et0_roYxsUGb35kpJhzaZ7Iz8_Y8WDGRM9v3zN29eH91foTv7j8-Hn97oJbVauZW0DshxYEKpIGq5r6jhpQ1UBU97ZpBuyU6kRnlegHxK6sG6lKQQOovkJ5xt4e2m6XbqLe5snRjHob3WTiTgfj9P2Kdxt9Hb7pBqQoG5kbvL5tEMPXJe-oJ5csjaPxFJakhcpTWoltmdFXD9CbsESft9OihLaFFmWVqZf_O7qz8ve8GRAHwMaQUqThDkHQ-wz1IUOdM9R_MtT72c0DkXWzmV3Yb-XGx6XyIE3bfVwU_9l-RPUbATqxmw |
| CitedBy_id | crossref_primary_10_1186_s13020_023_00772_2 crossref_primary_10_3390_cancers13184689 crossref_primary_10_1002_jcb_30477 crossref_primary_10_5306_wjco_v16_i4_101548 crossref_primary_10_1080_14728222_2025_2500420 crossref_primary_10_1016_j_jlr_2023_100479 crossref_primary_10_1016_j_dmd_2025_100141 crossref_primary_10_3389_fimmu_2023_1121864 |
| Cites_doi | 10.1021/cr200021m 10.1074/jbc.M201712200 10.1097/FPC.0b013e3282f50ee9 10.1038/clpt.2008.132 10.1111/bcp.12425 10.1248/bpb.28.1805 10.1208/s12248-018-0186-9 10.5414/cpp47709 10.5414/CP202193 10.2307/3001968 10.1016/j.ejphar.2008.01.042 10.1016/j.pharmthera.2012.12.007 10.1016/j.jsbmb.2019.03.009 10.1111/j.1365-2125.2008.03309.x 10.1111/bcp.13083 10.1046/j.1365-2125.1996.45111.x 10.1111/j.1558-5646.2012.01667.x 10.1124/dmd.118.082032 10.1517/17425255.2011.627854 10.1080/03602532.2016.1239630 10.5414/cpp42307 10.1067/mcp.2003.23 10.1021/mp4002415 10.1371/journal.pone.0056429 10.7554/eLife.07999 10.1093/nar/gkj067 10.1373/clinchem.2003.027607 10.1016/j.jchromb.2014.02.052 10.1038/clpt.2014.169 10.1194/jlr.M400239-JLR200 10.1111/bph.12856 10.1111/j.1365-2125.2010.03773.x 10.1124/dmd.113.052316 10.1124/dmd.104.000315 10.2165/0003088-200847120-00003 10.1016/s0014-5793(98)00247-6 10.1111/j.1365-2125.2011.04007.x 10.1097/00000539-199603000-00015 10.1002/hep.24391 10.1093/nar/gkx1037 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7TK 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s00228-020-03041-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-1041 |
| EndPage | 669 |
| ExternalDocumentID | PMC8032583 33201347 10_1007_s00228_020_03041_5 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Universitätsklinikum Bonn (8930) – fundername: ; |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECT EIHBH EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW Y6R YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY NPM 7TK 7U9 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c474t-c011df90214e3a167edbe8046fee7dc88f1b44b2bc42df11b5783452ef04d613 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000590240600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0031-6970 1432-1041 |
| IngestDate | Tue Nov 04 01:51:33 EST 2025 Sun Sep 28 08:29:16 EDT 2025 Tue Dec 02 15:55:48 EST 2025 Mon Jul 21 05:59:29 EDT 2025 Sat Nov 29 02:59:40 EST 2025 Tue Nov 18 22:51:23 EST 2025 Fri Feb 21 02:48:38 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Bile acid precursors Antifungal Cholesterol synthesis Cholesterol metabolism Cytochrome P450 Oxysterols |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-c011df90214e3a167edbe8046fee7dc88f1b44b2bc42df11b5783452ef04d613 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-0362-7330 0000-0002-7941-8308 |
| OpenAccessLink | https://link.springer.com/10.1007/s00228-020-03041-5 |
| PMID | 33201347 |
| PQID | 2509909136 |
| PQPubID | 47171 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8032583 proquest_miscellaneous_2461393195 proquest_journals_2509909136 pubmed_primary_33201347 crossref_primary_10_1007_s00228_020_03041_5 crossref_citationtrail_10_1007_s00228_020_03041_5 springer_journals_10_1007_s00228_020_03041_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-05-01 |
| PublicationDateYYYYMMDD | 2021-05-01 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | European journal of clinical pharmacology |
| PublicationTitleAbbrev | Eur J Clin Pharmacol |
| PublicationTitleAlternate | Eur J Clin Pharmacol |
| PublicationYear | 2021 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Godamudunage, Grech, Scott (CR34) 2018; 46 Niwa, Shiraga, Takagi (CR38) 2005; 28 Lutjohann, Hahn, Prange, Sudhop, Axelson, Sauerbruch, von Bergmann, Reichel (CR26) 2004; 42 Lee, Thornton, Sachs-Barrable, Kim, Wasan (CR40) 2013; 10 Diczfalusy, Kanebratt, Bredberg, Andersson, Bottiger, Bertilsson (CR16) 2009; 67 Neuvonen (CR4) 2010; 11 Varhe, Olkkola, Neuvonen (CR6) 1996; 42 Bodin, Andersson, Rystedt, Ellis, Norlin, Pikuleva, Eggertsen, Bjorkhem, Diczfalusy (CR30) 2002; 277 Bellamine, Lepesheva, Waterman (CR1) 2004; 45 Diczfalusy, Miura, Roh, Mirghani, Sayi, Larsson, Bodin, Allqvist, Jande, Kim, Aklillu, Gustafsson, Bertilsson (CR13) 2008; 18 Oertel, Vermehren, Huynh, Doehring, Ferreiros, Zimmermann, Geisslinger, Lotsch (CR20) 2014; 96 Gubbins (CR2) 2011; 7 Lamb, Kelly, Kelly (CR8) 1998; 425 Silvestro, Andersen, Schaller, Jensen (CR9) 2013; 8 Mackay, Jones, Myrie, Plat, Lutjohann (CR24) 2014; 957 CR36 Malhotra, Dickins, Alvey, Jumadilova, Li, Duczynski, Gandelman (CR39) 2011; 72 Wilcoxon (CR28) 1945; 1 Isoherranen, Kunze, Allen, Nelson, Thummel (CR35) 2004; 32 Sosic-Jurjevic, Lutjohann, Renko, Filipovic, Radulovic, Ajdzanovic, Trifunovic, Nestorovic, Zivanovic, Manojlovic Stojanoski, Khrle, Milosevic (CR25) 2019; 190 Gui, Miao, Thompson, Wahlgren, Mock, Stieger, Hagenbuch (CR41) 2008; 584 Curtis, Bond, Spina, Ahluwalia, Alexander, Giembycz, Gilchrist, Hoyer, Insel, Izzo, Lawrence, MacEwan, Moon, Wonnacott, Weston, McGrath (CR27) 2015; 172 Nes (CR11) 2011; 111 Kanebratt, Diczfalusy, Backstrom, Sparve, Bredberg, Bottiger, Andersson, Bertilsson (CR17) 2008; 84 Nivoix, Leveque, Herbrecht, Koffel, Beretz, Ubeaud-Sequier (CR3) 2008; 47 Oertel, Huynh, Hummel, Lotsch (CR23) 2015; 53 Bjorkhem-Bergman, Backstrom, Nylen, Ronquist-Nii, Bredberg, Andersson, Bertilsson, Diczfalusy (CR31) 2013; 41 Skarke, Kirchhof, Geisslinger, Lotsch (CR21) 2004; 50 Wishart, Knox, Guo, Shrivastava, Hassanali, Stothard, Chang, Woolsey (CR37) 2006; 34 Kasichayanula, Boulton, Luo, Rodrigues, Yang, Goodenough, Lee, Jemal, LaCreta (CR19) 2014; 78 Mao, Martin, McLeod, Nolan, van Horn, Vourvahis, Lin (CR14) 2017; 49 Vanhove, de Jonge, de Loor, Annaert, Diczfalusy, Kuypers (CR33) 2016; 82 CR42 Lutjohann, Marinova, Schneider, Oldenburg, von Bergmann, Bieber, Bjorkhem, Diczfalusy (CR18) 2009; 47 Olkkola, Ahonen, Neuvonen (CR5) 1996; 82 Nitta, Hashimoto, Kazuki, Takehara, Suzuki, Oshimura, Akita, Chiba, Kobayashi (CR15) 2018; 20 Mann, Whitney (CR29) 1947; 18 Diczfalusy, Nylen, Elander, Bertilsson (CR12) 2011; 71 Zanger, Schwab (CR22) 2013; 138 Rogers, Rocci, Haughey, Bertino (CR32) 2003; 73 Dupont, Lemetais, Ferreira, Cayot, Gervais, Beney (CR7) 2012; 66 Mitsche, McDonald, Hobbs, Cohen (CR10) 2015; 4 PO Gubbins (3041_CR2) 2011; 7 MA Mitsche (3041_CR10) 2015; 4 3041_CR36 H Mann (3041_CR29) 1947; 18 SI Nitta (3041_CR15) 2018; 20 KT Olkkola (3041_CR5) 1996; 82 S Dupont (3041_CR7) 2012; 66 Y Nivoix (3041_CR3) 2008; 47 PJ Neuvonen (3041_CR4) 2010; 11 B Sosic-Jurjevic (3041_CR25) 2019; 190 JF Rogers (3041_CR32) 2003; 73 K Bodin (3041_CR30) 2002; 277 D Lutjohann (3041_CR26) 2004; 42 J Mao (3041_CR14) 2017; 49 BG Oertel (3041_CR20) 2014; 96 MJ Curtis (3041_CR27) 2015; 172 SD Lee (3041_CR40) 2013; 10 L Bjorkhem-Bergman (3041_CR31) 2013; 41 U Diczfalusy (3041_CR16) 2009; 67 BG Oertel (3041_CR23) 2015; 53 T Niwa (3041_CR38) 2005; 28 C Skarke (3041_CR21) 2004; 50 DS Wishart (3041_CR37) 2006; 34 DC Lamb (3041_CR8) 1998; 425 F Wilcoxon (3041_CR28) 1945; 1 3041_CR42 WD Nes (3041_CR11) 2011; 111 C Gui (3041_CR41) 2008; 584 D Lutjohann (3041_CR18) 2009; 47 D Silvestro (3041_CR9) 2013; 8 KP Kanebratt (3041_CR17) 2008; 84 N Isoherranen (3041_CR35) 2004; 32 UM Zanger (3041_CR22) 2013; 138 A Bellamine (3041_CR1) 2004; 45 DS Mackay (3041_CR24) 2014; 957 A Varhe (3041_CR6) 1996; 42 T Vanhove (3041_CR33) 2016; 82 S Kasichayanula (3041_CR19) 2014; 78 MP Godamudunage (3041_CR34) 2018; 46 B Malhotra (3041_CR39) 2011; 72 U Diczfalusy (3041_CR12) 2011; 71 U Diczfalusy (3041_CR13) 2008; 18 |
| References_xml | – volume: 111 start-page: 6423 issue: 10 year: 2011 end-page: 6451 ident: CR11 article-title: Biosynthesis of cholesterol and other sterols publication-title: Chem Rev doi: 10.1021/cr200021m – volume: 277 start-page: 31534 issue: 35 year: 2002 end-page: 31540 ident: CR30 article-title: Metabolism of 4 beta -hydroxycholesterol in humans publication-title: J Biol Chem doi: 10.1074/jbc.M201712200 – volume: 18 start-page: 201 issue: 3 year: 2008 end-page: 208 ident: CR13 article-title: 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3282f50ee9 – volume: 84 start-page: 589 issue: 5 year: 2008 end-page: 594 ident: CR17 article-title: Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.132 – volume: 78 start-page: 1122 issue: 5 year: 2014 end-page: 1134 ident: CR19 article-title: Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12425 – volume: 28 start-page: 1805 issue: 9 year: 2005 end-page: 1808 ident: CR38 article-title: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes publication-title: Biol Pharm Bull doi: 10.1248/bpb.28.1805 – volume: 18 start-page: 50 year: 1947 end-page: 60 ident: CR29 article-title: On a test of whether one of two random variables is stochastically larger than the other publication-title: Ann Math Stat doi: 10.1208/s12248-018-0186-9 – volume: 47 start-page: 709 issue: 12 year: 2009 end-page: 715 ident: CR18 article-title: 4Beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man publication-title: Int J Clin Pharmacol Ther doi: 10.5414/cpp47709 – volume: 53 start-page: 13 issue: 1 year: 2015 end-page: 20 ident: CR23 article-title: Lack of fluconazole effects on human chemosensation publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CP202193 – volume: 1 start-page: 80 year: 1945 end-page: 83 ident: CR28 article-title: Individual comparisons by ranking methods publication-title: Biom Bull doi: 10.2307/3001968 – volume: 584 start-page: 57 issue: 1 year: 2008 end-page: 65 ident: CR41 article-title: Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2008.01.042 – volume: 138 start-page: 103 issue: 1 year: 2013 end-page: 141 ident: CR22 article-title: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2012.12.007 – volume: 190 start-page: 1 year: 2019 end-page: 10 ident: CR25 article-title: The isoflavones genistein and daidzein increase hepatic concentration of thyroid hormones and affect cholesterol metabolism in middle-aged male rats publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2019.03.009 – volume: 67 start-page: 38 issue: 1 year: 2009 end-page: 43 ident: CR16 article-title: 4Beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2008.03309.x – volume: 82 start-page: 1539 issue: 6 year: 2016 end-page: 1549 ident: CR33 article-title: Comparative performance of oral midazolam clearance and plasma 4beta-hydroxycholesterol to explain interindividual variability in tacrolimus clearance publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13083 – volume: 42 start-page: 465 issue: 4 year: 1996 end-page: 470 ident: CR6 article-title: Effect of fluconazole dose on the extent of fluconazole-triazolam interaction publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1996.45111.x – volume: 66 start-page: 2961 issue: 9 year: 2012 end-page: 2968 ident: CR7 article-title: Ergosterol biosynthesis: a fungal pathway for life on land? publication-title: Evolution doi: 10.1111/j.1558-5646.2012.01667.x – volume: 20 start-page: 61 issue: 3 year: 2018 ident: CR15 article-title: Evaluation of 4beta-hydroxycholesterol and 25-hydroxycholesterol as endogenous biomarkers of CYP3A4: study with CYP3A-humanized mice publication-title: AAPS J doi: 10.1208/s12248-018-0186-9 – volume: 46 start-page: 1329 issue: 9 year: 2018 end-page: 1337 ident: CR34 article-title: Comparison of antifungal azole interactions with adult cytochrome P450 3A4 versus neonatal cytochrome P450 3A7 publication-title: Drug Metab Dispos doi: 10.1124/dmd.118.082032 – volume: 7 start-page: 1411 issue: 11 year: 2011 end-page: 1429 ident: CR2 article-title: Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450 publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.2011.627854 – ident: CR42 – volume: 49 start-page: 18 issue: 1 year: 2017 end-page: 34 ident: CR14 article-title: Perspective: 4beta-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A publication-title: Drug Metab Rev doi: 10.1080/03602532.2016.1239630 – volume: 42 start-page: 307 issue: 6 year: 2004 end-page: 313 ident: CR26 article-title: Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men publication-title: Int J Clin Pharmacol Ther doi: 10.5414/cpp42307 – volume: 73 start-page: 153 issue: 3 year: 2003 end-page: 158 ident: CR32 article-title: An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2003.23 – volume: 10 start-page: 3203 issue: 8 year: 2013 end-page: 3212 ident: CR40 article-title: Evaluation of the contribution of the ATP binding cassette transporter, P-glycoprotein, to in vivo cholesterol homeostasis publication-title: Mol Pharm doi: 10.1021/mp4002415 – volume: 8 start-page: e56429 issue: 2 year: 2013 ident: CR9 article-title: Plant sterol metabolism. delta(7)-sterol-C5-desaturase (STE1/DWARF7), delta(5,7)-sterol-delta(7)-reductase (DWARF5) and delta(24)-sterol-delta(24)-reductase (DIMINUTO/DWARF1) show multiple subcellular localizations in Arabidopsis thaliana (Heynh) L publication-title: PLoS One doi: 10.1371/journal.pone.0056429 – volume: 4 start-page: e07999 year: 2015 ident: CR10 article-title: Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways publication-title: Elife doi: 10.7554/eLife.07999 – volume: 34 start-page: D668 issue: Database issue year: 2006 end-page: D672 ident: CR37 article-title: DrugBank: a comprehensive resource for in silico drug discovery and exploration publication-title: Nucleic Acids Res doi: 10.1093/nar/gkj067 – volume: 50 start-page: 640 issue: 3 year: 2004 end-page: 644 ident: CR21 article-title: Comprehensive mu-opioid-receptor genotyping by pyrosequencing publication-title: Clin Chem doi: 10.1373/clinchem.2003.027607 – volume: 957 start-page: 116 year: 2014 end-page: 122 ident: CR24 article-title: Methodological considerations for the harmonization of non-cholesterol sterol bio-analysis publication-title: J Chromatogr B Anal Technol Biomed Life Sci doi: 10.1016/j.jchromb.2014.02.052 – volume: 96 start-page: 684 issue: 6 year: 2014 end-page: 693 ident: CR20 article-title: Cytochrome P450 epoxygenase dependence of opioid analgesia: fluconazole does not interfere with remifentanil-mediated analgesia in human subjects publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.169 – volume: 45 start-page: 2000 issue: 11 year: 2004 end-page: 2007 ident: CR1 article-title: Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology publication-title: J Lipid Res doi: 10.1194/jlr.M400239-JLR200 – volume: 172 start-page: 3461 issue: 14 year: 2015 end-page: 3471 ident: CR27 article-title: Experimental design and analysis and their reporting: new guidance for publication in BJP publication-title: Br J Pharmacol doi: 10.1111/bph.12856 – volume: 71 start-page: 183 issue: 2 year: 2011 end-page: 189 ident: CR12 article-title: 4Beta-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2010.03773.x – ident: CR36 – volume: 11 start-page: 323 issue: 3 year: 2010 end-page: 332 ident: CR4 article-title: Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics publication-title: Curr Opin Investig Drugs – volume: 41 start-page: 1488 issue: 8 year: 2013 end-page: 1493 ident: CR31 article-title: Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin publication-title: Drug Metab Dispos doi: 10.1124/dmd.113.052316 – volume: 32 start-page: 1121 issue: 10 year: 2004 end-page: 1131 ident: CR35 article-title: Role of itraconazole metabolites in CYP3A4 inhibition publication-title: Drug Metab Dispos doi: 10.1124/dmd.104.000315 – volume: 47 start-page: 779 issue: 12 year: 2008 end-page: 792 ident: CR3 article-title: The enzymatic basis of drug-drug interactions with systemic triazole antifungals publication-title: Clin Pharmacokinet doi: 10.2165/0003088-200847120-00003 – volume: 425 start-page: 263 issue: 2 year: 1998 end-page: 265 ident: CR8 article-title: Molecular diversity of sterol 14alpha-demethylase substrates in plants, fungi and humans publication-title: FEBS Lett doi: 10.1016/s0014-5793(98)00247-6 – volume: 72 start-page: 263 issue: 2 year: 2011 end-page: 269 ident: CR39 article-title: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.04007.x – volume: 82 start-page: 511 issue: 3 year: 1996 end-page: 516 ident: CR5 article-title: The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam publication-title: Anesth Analg doi: 10.1097/00000539-199603000-00015 – volume: 46 start-page: 1329 issue: 9 year: 2018 ident: 3041_CR34 publication-title: Drug Metab Dispos doi: 10.1124/dmd.118.082032 – volume: 84 start-page: 589 issue: 5 year: 2008 ident: 3041_CR17 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.132 – volume: 4 start-page: e07999 year: 2015 ident: 3041_CR10 publication-title: Elife doi: 10.7554/eLife.07999 – volume: 190 start-page: 1 year: 2019 ident: 3041_CR25 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2019.03.009 – volume: 138 start-page: 103 issue: 1 year: 2013 ident: 3041_CR22 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2012.12.007 – volume: 72 start-page: 263 issue: 2 year: 2011 ident: 3041_CR39 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.04007.x – volume: 111 start-page: 6423 issue: 10 year: 2011 ident: 3041_CR11 publication-title: Chem Rev doi: 10.1021/cr200021m – volume: 10 start-page: 3203 issue: 8 year: 2013 ident: 3041_CR40 publication-title: Mol Pharm doi: 10.1021/mp4002415 – volume: 47 start-page: 779 issue: 12 year: 2008 ident: 3041_CR3 publication-title: Clin Pharmacokinet doi: 10.2165/0003088-200847120-00003 – ident: 3041_CR42 doi: 10.1002/hep.24391 – volume: 32 start-page: 1121 issue: 10 year: 2004 ident: 3041_CR35 publication-title: Drug Metab Dispos doi: 10.1124/dmd.104.000315 – volume: 78 start-page: 1122 issue: 5 year: 2014 ident: 3041_CR19 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12425 – volume: 53 start-page: 13 issue: 1 year: 2015 ident: 3041_CR23 publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CP202193 – volume: 7 start-page: 1411 issue: 11 year: 2011 ident: 3041_CR2 publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.2011.627854 – volume: 20 start-page: 61 issue: 3 year: 2018 ident: 3041_CR15 publication-title: AAPS J doi: 10.1208/s12248-018-0186-9 – volume: 50 start-page: 640 issue: 3 year: 2004 ident: 3041_CR21 publication-title: Clin Chem doi: 10.1373/clinchem.2003.027607 – volume: 277 start-page: 31534 issue: 35 year: 2002 ident: 3041_CR30 publication-title: J Biol Chem doi: 10.1074/jbc.M201712200 – volume: 28 start-page: 1805 issue: 9 year: 2005 ident: 3041_CR38 publication-title: Biol Pharm Bull doi: 10.1248/bpb.28.1805 – volume: 49 start-page: 18 issue: 1 year: 2017 ident: 3041_CR14 publication-title: Drug Metab Rev doi: 10.1080/03602532.2016.1239630 – volume: 82 start-page: 1539 issue: 6 year: 2016 ident: 3041_CR33 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13083 – volume: 18 start-page: 50 year: 1947 ident: 3041_CR29 publication-title: Ann Math Stat doi: 10.1208/s12248-018-0186-9 – volume: 957 start-page: 116 year: 2014 ident: 3041_CR24 publication-title: J Chromatogr B Anal Technol Biomed Life Sci doi: 10.1016/j.jchromb.2014.02.052 – volume: 66 start-page: 2961 issue: 9 year: 2012 ident: 3041_CR7 publication-title: Evolution doi: 10.1111/j.1558-5646.2012.01667.x – volume: 45 start-page: 2000 issue: 11 year: 2004 ident: 3041_CR1 publication-title: J Lipid Res doi: 10.1194/jlr.M400239-JLR200 – volume: 47 start-page: 709 issue: 12 year: 2009 ident: 3041_CR18 publication-title: Int J Clin Pharmacol Ther doi: 10.5414/cpp47709 – ident: 3041_CR36 doi: 10.1093/nar/gkx1037 – volume: 11 start-page: 323 issue: 3 year: 2010 ident: 3041_CR4 publication-title: Curr Opin Investig Drugs – volume: 67 start-page: 38 issue: 1 year: 2009 ident: 3041_CR16 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2008.03309.x – volume: 1 start-page: 80 year: 1945 ident: 3041_CR28 publication-title: Biom Bull doi: 10.2307/3001968 – volume: 18 start-page: 201 issue: 3 year: 2008 ident: 3041_CR13 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3282f50ee9 – volume: 41 start-page: 1488 issue: 8 year: 2013 ident: 3041_CR31 publication-title: Drug Metab Dispos doi: 10.1124/dmd.113.052316 – volume: 71 start-page: 183 issue: 2 year: 2011 ident: 3041_CR12 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2010.03773.x – volume: 42 start-page: 307 issue: 6 year: 2004 ident: 3041_CR26 publication-title: Int J Clin Pharmacol Ther doi: 10.5414/cpp42307 – volume: 73 start-page: 153 issue: 3 year: 2003 ident: 3041_CR32 publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2003.23 – volume: 425 start-page: 263 issue: 2 year: 1998 ident: 3041_CR8 publication-title: FEBS Lett doi: 10.1016/s0014-5793(98)00247-6 – volume: 172 start-page: 3461 issue: 14 year: 2015 ident: 3041_CR27 publication-title: Br J Pharmacol doi: 10.1111/bph.12856 – volume: 8 start-page: e56429 issue: 2 year: 2013 ident: 3041_CR9 publication-title: PLoS One doi: 10.1371/journal.pone.0056429 – volume: 96 start-page: 684 issue: 6 year: 2014 ident: 3041_CR20 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.169 – volume: 82 start-page: 511 issue: 3 year: 1996 ident: 3041_CR5 publication-title: Anesth Analg doi: 10.1097/00000539-199603000-00015 – volume: 34 start-page: D668 issue: Database issue year: 2006 ident: 3041_CR37 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkj067 – volume: 584 start-page: 57 issue: 1 year: 2008 ident: 3041_CR41 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2008.01.042 – volume: 42 start-page: 465 issue: 4 year: 1996 ident: 3041_CR6 publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1996.45111.x |
| SSID | ssj0015903 |
| Score | 2.3665166 |
| Snippet | Purpose
The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic... The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome... PurposeThe antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 659 |
| SubjectTerms | Antifungal agents Biomedical and Life Sciences Biomedicine Cholesterol Clinical Trial Cytochrome P450 Demethylation Dosage Fluconazole Gas chromatography Hemopoiesis Itraconazole Ketoconazole Lanosterol Lipid metabolism Liver Mass spectroscopy Pharmacology/Toxicology Placebos Sterols |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LTxsxEB61lEMvQEsp4VG5EuJCLK3X3th7RAjEAUVRGyFuq_WuLSLBpsomSOFn8UP4TYy9jyiEIrVnj73r8bysmfkMcCRl2mPMKmo1t1SkDgMSjSJVOkCbmeYR96A-11ey31c3N_Ggbgorm2r3JiXpLXXb7OahWqi77rh0HqPRR_iE7k45dfz1-7rNHURxUEPtMtqLZVC3yry9xrI7WokxV0slX-VLvRu62Py_DWzBRh12ktNKTr7AB1N8heNBhVs975Lhog2r7JJjMlggWs-34QwtyuyeiOcnejvPXeGLM5oeY2F8R0aFizxLU5Kq55FYVwZfpI9IQtpC9m8wvDgfnl3S-vUFmgkppjRDzc9t7DDVDE9ZT5pcG4XXaWuMzDOlLNNC6FBnIswtYzpyb3ZEobGByDFI2IG1YlyYXSBKMxNoZYJUSaGMg8LNI43MMALDmyDqAGvOIMlqZHL3QMZd0mIqe9YlSJx41iU456Sd86fC5XiX-qA52qTW0TLB4A9dccx4rwM_22HULpcySQszniGNwJ3EaKZwie-VJLSf4xyDJy5kB-SSjLQEDrl7eaQY3XoEbxXwMFK8A91GUha_9fdd7P0b-T58Dl0Bjq_OPIC16WRmDmE9e5iOyskPrzMvJowQvQ priority: 102 providerName: Springer Nature |
| Title | Serum 4β-hydroxycholesterol increases during fluconazole treatment |
| URI | https://link.springer.com/article/10.1007/s00228-020-03041-5 https://www.ncbi.nlm.nih.gov/pubmed/33201347 https://www.proquest.com/docview/2509909136 https://www.proquest.com/docview/2461393195 https://pubmed.ncbi.nlm.nih.gov/PMC8032583 |
| Volume | 77 |
| WOSCitedRecordID | wos000590240600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-1041 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015903 issn: 0031-6970 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NjtMwEB6xXQ5c-P8pLCsjob1Qizh2aueEYLUrDqiqSlX1FsWJo620pMumRSqPxYPwTMw4bqqyYi9cLEUeJ7HG_jz2jL8BeKt1PhSiMryysuIqJw5IBEVubISYmZeJ9KQ-sy96NDLzeToOB25NCKvcYqIH6nJZ0Bn5e1yqEThTIYcfrr5zyhpF3tWQQuMADompTPXg8NPZaDzp_AhJGgXaXcGHqY7CtRl_ec5Tv3DaPpF7UPBkf2m6YW_eDJv8y3fql6TzB__bmYdwPxij7GM7eh7BHVc_hpNxy2a9GbDp7nJWM2AnbLzjud48gVPEmfU3pn7_4hebksJhCEo988Lyki1qskcb17D2JiSrKDi-zn-iCOvC25_C9PxsevqZh5wMvFBarXiBeFBWKTGtOZmLoXaldQY32ZVzuiyMqYRVysa2UHFZCWETyuSRxK6KVImmwzPo1cvavQBmrHCRNS7KjVbGEUFumVjUiVNo9ERJH8RWG1kR-MopbcZl1jEtew1mKJx5DWbY5l3X5qpl67hV-mirnSzM3CbbqaYPb7pqnHPkSMlrt1yjjMKepAhe-Irn7ZjoPiclmlRS6T7ovdHSCRCf935NvbjwvN4mknFiZB8G23G1-61_9-Ll7b14BfdiCsPxMZpH0Ftdr91ruFv8WC2a62M40JMZlXPtS3McZhA-Tb7O_gBnMCA1 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VggQX3o9AgUWCXsgKr73Org8IoULVqiGKUFT1Znm9azVScUqdgMJ_4sIP4Tcxs35EoaK3Hjh7_Nj48zezmZlvAF4qlQ2EKDQvTFRwmZEGJJIi1yZAzsxsHHlRn8OhGo300VEy3oCfbS8MlVW2nOiJ2s5y-o_8DbpqJM5ERIN3p185TY2i7Go7QqOGxYFbfsctW_V2_wO-31dhuPtxsrPHm6kCPJdKznmOiLZFQlphLsrEQDlrnMZtYuGcsrnWhTBSmtDkMrSFECamWRRx6IpAWnR-eNkrcBVpXFAFmfp82CUt4iRoNH4FHyQqaHp0fKee15nhtFejXKTg8bofPBfcnq_R_CtR6_3f7q3_7Je7DTebQJu9r7-MO7DhyruwPa6Vupd9Nlk1nlV9ts3GKw3v5T3YQQ5dfGHy9y9-vLRU6kNuwqtKzE7YtKRYu3IVq7s8WUGF_2X2A01YV7p_HyaXsb4HsFnOSvcImDbCBUa7INNKakfivzY2CAEnMaAL4h6I9uWneaPFTiNBTtJORdoDJkXj1AMmxXNed-ec1kokF1pvtWBIG1aq0hUSevCiO4x8QkmirHSzBdpIXEmCxIyXeFhDsLtdFGG4GEnVA7UGzs6AtMrXj5TTY69ZroMojHXUg34L49Vj_XsVjy9exXO4vjf5NEyH-6ODJ3AjpHIjX4u6BZvzs4V7Ctfyb_NpdfbMf6gM0kuG9x9x-Hd9 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFCEuvB-BAosEvZBVvfY6uz4gBG0jqlaRhSLUm-X17qqRilPqBBR-Fjf-BL-J2fUjChW99cDZ48cmn7-Z9cx8A_BKiHzImJXUqshSnjsNSCRFKlWAnJnrOPKiPp-PxHgsj4-TdAN-tb0wrqyy5URP1HpWuG_kO-iqkTgTFg13bFMWke6N3p19pW6ClMu0tuM0aogcmuV33L5Vbw_28L9-HYaj_cnuR9pMGKAFF3xOC0S3tonTDTNRzobCaGUkbhmtMUIXUlqmOFehKnioLWMqdnMp4tDYgGt0hHjZa7ApMMaIe7D5YX-cfupSGHESNIq_jA4TETQdO75vz6vOULdzc5lJRuN1r3gh1L1YsflX2tZ7w9Ht__h3vAO3mhCcvK_fmbuwYcp7sJ3WGt7LAZmsWtKqAdkm6Urde3kfdpFdF18I__2Tniy1KwJyDsTrTcxOybR0UXhlKlL3fxLrWgLK_AeakK6o_wFMrmJ9D6FXzkrzGIhUzARKmiCXgkvjZIF1rBAOhmOoF8R9YC0QsqJRaXfDQk6zTl_agydD48yDJ8Nz3nTnnNUaJZdab7XAyBq-qrIVKvrwsjuMTOPSR3lpZgu04biSBCkbL_GohmN3uyjCQDLiog9iDaidgVMxXz9STk-8mrkMojCWUR8GLaRXj_XvVTy5fBUv4AaiOjs6GB8-hZuhq0PyRapb0JufL8wzuF58m0-r8-fNW0sgu2J8_wFicIFx |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+4%CE%B2-hydroxycholesterol+increases+during+fluconazole+treatment&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=L%C3%BCtjohann%2C+Dieter&rft.au=Stellaard%2C+Frans&rft.au=Kerksiek%2C+Anja&rft.au=L%C3%B6tsch%2C+J%C3%B6rn&rft.date=2021-05-01&rft.issn=1432-1041&rft.eissn=1432-1041&rft.volume=77&rft.issue=5&rft.spage=659&rft_id=info:doi/10.1007%2Fs00228-020-03041-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |